What is Zacks Research’s Forecast for Revvity Q1 Earnings?

Revvity Inc. (NYSE:RVTY) – Research analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for shares of Revvity in a research report issued to clients and investors on Monday, February 23rd. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.03 for the quarter, down from their prior estimate of $1.11. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s Q4 2026 earnings at $1.69 EPS, Q2 2027 earnings at $1.48 EPS, Q3 2027 earnings at $1.45 EPS, Q4 2027 earnings at $1.69 EPS, FY2027 earnings at $5.90 EPS and FY2028 earnings at $6.81 EPS.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, February 2nd. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $772.06 million during the quarter, compared to analysts’ expectations of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company posted $1.42 earnings per share. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS.

RVTY has been the topic of several other reports. Robert W. Baird set a $129.00 price target on Revvity in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. lifted their target price on Revvity from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Tuesday, February 3rd. Barclays increased their price target on shares of Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Finally, Bank of America lowered shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a research note on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Revvity presently has an average rating of “Hold” and a consensus price target of $113.67.

Revvity Trading Up 0.0%

NYSE RVTY opened at $97.63 on Wednesday. The firm’s 50 day moving average price is $103.21 and its two-hundred day moving average price is $96.30. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. Revvity has a twelve month low of $81.36 and a twelve month high of $120.39. The stock has a market cap of $11.07 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 2.07 and a beta of 1.07.

Institutional Trading of Revvity

Hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. increased its position in Revvity by 4.7% in the 4th quarter. Pacer Advisors Inc. now owns 11,152 shares of the company’s stock worth $1,079,000 after buying an additional 504 shares during the period. Virtu Financial LLC acquired a new stake in shares of Revvity in the fourth quarter worth $384,000. Corient Private Wealth LLC increased its position in Revvity by 985.8% during the fourth quarter. Corient Private Wealth LLC now owns 126,664 shares of the company’s stock worth $12,245,000 after acquiring an additional 114,999 shares during the period. Alberta Investment Management Corp acquired a new position in Revvity during the 4th quarter valued at $1,442,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in Revvity by 10.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 15,656 shares of the company’s stock valued at $1,515,000 after purchasing an additional 1,480 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s payout ratio is presently 13.46%.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 beat and upbeat 2026 outlook underpin investor sentiment — coverage pieces note Revvity’s better‑than‑expected Q4 results and management’s favorable FY‑2026 guidance, which helps justify the stock’s premium relative to near‑term estimates. How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook
• Positive Sentiment: Zacks raised its Q4 2026 estimate (to $1.69 from $1.58) — a lift to that quarter’s outlook that partially offsets other cuts and signals some confidence in Revvity’s late‑2026 trajectory. (Zacks Research note)
• Neutral Sentiment: Analyst sentiment overview stories are circulating assessing how Wall Street views Revvity’s prospects — these articles summarize buy/hold/sell distribution but don’t report major new analyst actions. Do Wall Street analysts like Revvity stock?
• Neutral Sentiment: Comparative coverage (Progyny vs. Revvity) offers cross‑sector context for investors considering relative exposure but doesn’t materially change Revvity’s fundamentals. Financial Comparison: Progyny (NASDAQ:PGNY) vs. Revvity (NYSE:RVTY)
• Negative Sentiment: Zacks trimmed several near‑term EPS estimates (Q1‑2026: from $1.11 to $1.03; Q2‑2027: 1.51→1.48; Q3‑2027: 1.48→1.45; Q4‑2027: 1.72→1.69) and lowered FY‑2027 to $5.90 from $5.97 — these cuts are modest but signal slightly reduced growth expectations and could pressure sentiment if other shops follow. (Zacks Research notes)

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.